{
    "cancer_info": {
        "cancer_name": "Malignant Pleural Mesothelioma"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Contrast-enhanced chest CT",
            "FDG-PET/CT (must precede pleurodesis)",
            "MRI (optional for chest wall/spinal/diaphragmatic/vascular invasion)",
            "Brain MRI (if neurologic symptoms)",
            "Thoracoscopic biopsy (preferred)",
            "CT-guided core biopsy",
            "Open biopsy",
            "EBUS/EUS-FNA (mediastinal lymph node assessment)",
            "Mediastinoscopy",
            "VATS/laparoscopy (if contralateral/peritoneal involvement suspected)",
            "Thoracentesis for pleural effusion assessment",
            "IHC panel (WT1, calretinin, D2-40, CEA, TTF-1, claudin-4)",
            "BAP1 loss testing (IHC)",
            "MTAP loss testing (IHC)",
            "CDKN2A FISH testing",
            "Molecular profiling (NF2, CDKN2A deletions, ALK/NTRK fusions)",
            "Soluble mesothelin-related peptide (SMRP) testing",
            "Pulmonary function tests (PFTs) including DLCO",
            "Cardiac stress test"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage I-IIIA epithelioid",
            "risk_group": "Operable candidates (FEV1 >80%, adequate cardiac function)",
            "treatment_plans": [
                {
                    "treatment_line": "Multimodality therapy",
                    "patient_subgroup": "Surgical candidates",
                    "plan_name": "Pleurectomy/Decortication (P/D) ± sequential pleural IMRT",
                    "plan_details": "Lung-sparing surgery; IMRT at experienced centers only",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred for operable patients"
                },
                {
                    "treatment_line": "Trimodality therapy",
                    "patient_subgroup": "Surgical candidates",
                    "plan_name": "Neoadjuvant chemotherapy → Surgery → Adjuvant IMRT",
                    "plan_details": "Pemetrexed + Cisplatin/Carboplatin induction → P/D/EPP → Hemithoracic IMRT (45-60 Gy)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Primary therapy",
                    "patient_subgroup": "Non-surgical candidates",
                    "plan_name": "Systemic therapy + Pleural IMRT",
                    "plan_details": "Platinum-based chemotherapy + IMRT (20-40 Gy)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IIIB-IV, sarcomatoid/biphasic, or medically inoperable",
            "risk_group": "Unfavorable prognosis",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Epithelioid histology",
                    "plan_name": "Nivolumab + Ipilimumab",
                    "plan_details": "Immunotherapy combination (CheckMate 743 regimen)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Epithelioid histology",
                    "plan_name": "Platinum + Pemetrexed ± Bevacizumab",
                    "plan_details": "Cisplatin 75mg/m² or Carboplatin AUC 5 + Pemetrexed 500mg/m²",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Sarcomatoid/biphasic histology",
                    "plan_name": "Nivolumab + Ipilimumab",
                    "plan_details": "First-line immunotherapy for aggressive subtypes",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "Any histology after progression",
                    "plan_name": "Nivolumab ± Ipilimumab",
                    "plan_details": "Immunotherapy rechallenge for prior responders",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "Any histology",
                    "plan_name": "Pemetrexed rechallenge",
                    "plan_details": "If prior response to pemetrexed-based therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Palliative care",
                    "patient_subgroup": "Symptomatic patients",
                    "plan_name": "Palliative RT",
                    "plan_details": "20-40 Gy for pain/obstruction management",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "Diagnostic: BAP1 loss (specific for mesothelioma), MTAP loss (surrogate for CDKN2A deletion), IHC panel (WT1/calretinin/D2-40 for mesothelial differentiation)",
            "Prognostic: Epithelioid histology and BAP1 loss correlate with better survival; Sarcomatoid histology and CDKN2A loss indicate poor prognosis",
            "Predictive: ALK/NTRK fusions (<1%) indicate response to TRK/ALK inhibitors; PD-L1 expression has unclear predictive value for immunotherapy",
            "Therapeutic targeting: Molecular profiling recommended to identify rare actionable alterations (e.g., ALK/NTRK) for clinical trials"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：间皮瘤：胸膜.txt"
}